This CME-accredited activity, Malignant Hematology, is designed to enhance the knowledge and clinical competence of healthcare professionals involved in the care of patients with malignant hematologic disorders. The course will focus on acute myeloid leukemia (AML), its precursor conditions such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), as well as acute lymphoblastic leukemia (ALL). Participants will receive up-to-date, evidence-based insights into diagnostic and therapeutic advances, with an emphasis on a multidisciplinary, patient-centered approach. This activity is intended for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare providers involved in the management of hematologic malignancies.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Michael Haddadin (MD)
Dr. Michael M. Haddadin is an Assistant Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center, where he serves as a clinical and translational researcher and practicing oncologist. He earned his MBBS from the Jordan University of Science and Technology in 2014 and is currently pursuing a Master of Science in Clinical and Translational Research at the University of Nebraska. Dr. Haddadin completed his residency in Internal Medicine at SUNY Downstate Health Sciences University, followed by a fellowship in Hematology-Oncology at the University of Massachusetts, where he served as Chief Fellow. He previously held the role of Chief Resident at King Hussein Cancer Center in Jordan. Board-certified in Internal Medicine, Hematology, and Medical Oncology, Dr. Haddadin holds active medical licenses in Nebraska and Michigan. His research interests include acute myeloid leukemia, graft-versus-host disease, and precision oncology. He is an active site primary investigator on multiple industry-sponsored and cooperative group clinical trials. His contributions to academic medicine include reviewer roles for Cancer Letter and Current Problems in Cancer, as well as participation in the prestigious ASCO/AACR Methods in Clinical Cancer Research Workshop. Dr. Haddadin is a recipient of several honors, including the AFMR Internal Medicine Research Award and a full medical scholarship from the Jordanian Ministry of Higher Education.
Disclosure
Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.
- Medical oncologists
- Surgical oncologists
- Oncology residents/fellows
- Oncology NPs/Pas
- Oncology pharmacists
Target Audience
- Identify and apply current diagnostic and therapeutic strategies for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), and acute lymphoblastic leukemia (ALL).
- Recognize molecular and genetic targets that inform risk stratification and personalized treatment in malignant hematology.
- Evaluate the role of newly approved therapies and emerging agents in the context of evidence-based, patient-centered care.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: